华润医药(03320.HK)收购英特集团(000411.SZ)830万股持股达20%
格隆汇7月16日丨华润医药(03320.HK)发布公告,于2019年7月9日,公司全资附属华润医药商业集团有限公司分别以人民币大约7529万元及人民币1815万元从浙江省中医药健康产业集团有限公司及浙江华辰投资发展有限公司以收购其项下的浙江英特集团股份有限公司(000411.SZ)股份668.6万股及161.2万股(深圳证券交易所,股票代码:000411),每股价格为人民币11.26元。
连同华润医药商业于2019年6月26日以每股价格人民币11.26元缴款认购英特集团非公开发行股份4149万股,华润医药商业于本公告当日合共持有英特集团股份4978.8万股,占英特集团增发之后的总股本的20%。2019年6月26日及2019年7月9日的交易总额为人民币5.6亿元。
公司称,英特集团作为浙江省医药流通行业区域龙头企业之一,具备良好的业务基础及合作平台,华润医药商业可借助双方未来的战略合作,充分实现优势互补及强强联合及全面提升华润医药商业的运作效率以及竞争能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.